Nasus Pharma CEO Issues 2025 Letter to Shareholders [Yahoo! Finance]
AptarGroup, Inc. (ATR)
Last aptargroup, inc. earnings: 4/30 05:04 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.aptar.com
Company Research
Source: Yahoo! Finance
pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman. Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We've made considerable progress building a strong, focused company with significant clinical impact, by developing drug delivery products based on our proprietary Nasax powder technology, which has the potential to enhance intranasal drug absorption for improved outcomes. We began 2025 by presenting integrated data from two early clinical trials of NS002, our investigational intranasal epinephrine powder formulation, designed to address limitations of injectable Epinephrine, developed as a needle-free, easy-to-administer alternative to traditional epinephrine autoinjectors. The positive results show NS002 has demonstrated the potential for faster and higher absorption of epinephrine in a clinic set
Show less
Read more
Impact Snapshot
Event Time:
ATR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATR alerts
High impacting AptarGroup, Inc. news events
Weekly update
A roundup of the hottest topics
ATR
News
- Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)Business Wire
- Has AptarGroup's Share Price Slide Created a New Opportunity in 2025? [Yahoo! Finance]Yahoo! Finance
- AptarGroup (ATR): Revisiting Valuation After Mixed 2024 Performance and Recent Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive YearBusiness Wire
- Aptar acquires oral dosing pharma packaging solutions provider Sommaplast [Seeking Alpha]Seeking Alpha
ATR
Earnings
- 10/30/25 - Beat
ATR
Sec Filings
- 12/15/25 - Form 4
- 12/12/25 - Form 144
- 11/20/25 - Form 8-K
- ATR's page on the SEC website